Physician profile
Prashant Morolia
NPI 1790032852
$719.83
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $134 · 2023: $481 · 2024: $105.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $586.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $586.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $172.94 | 2023 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $90.39 | 2023-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Abbvie INC. | $70.09 | 2022-2023 | |
| Lilly USA, LLC | $53.65 | 2022-2023 | Jardiance, Mounjaro |
| Astellas Pharma US INC | $51.11 | 2023 | Myrbetriq, Veozah |
| Exact Sciences Corporation | $41.70 | 2023-2024 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.62 | 2022-2023 | Synjardy, Jardiance |
| Ethicon INC. | $35.46 | 2023 | Monarch Platform |
| Pfizer INC. | $30.42 | 2023 | |
| Astrazeneca Pharmaceuticals Lp | $29.70 | 2023 | Farxiga |
| Dexcom, INC. | $28.84 | 2022-2023 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $19.32 | 2022 | |
| Heartflow, INC. | $18.26 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.56 | 2023 | |
| Merck Sharp & Dohme LLC | $16.16 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $5.61 | 2023 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prashant Morolia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.